Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Ippoliti, C' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 56 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Quilitz, RE; Arnold, AD; Briones, GR; Dix, SP; Ippoliti, C; Kennedy, LD; Lucich, JL; Mehta, J; Peters, BG; Tice, DS
      Practice guidelines for lipid-based amphotericin B in stem cell transplantrecipients

      ANNALS OF PHARMACOTHERAPY
    2. Khouri, IF; Saliba, RM; Giralt, SA; Lee, MS; Okoroji, GJ; Hagemeister, FB; Korbling, M; Younes, A; Ippoliti, C; Gajewski, JL; McLaughlin, P; Anderlini, P; Donato, ML; Cabanillas, FF; Champlin, RE
      Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

      BLOOD
    3. Przepiorka, D; Saliba, R; Cleary, K; Fischer, H; Tonai, R; Fritsche, H; Khouri, IF; Folloder, J; Ueno, NT; Mehra, R; Ippoliti, C; Giralt, S; Gajewski, J; Donato, M; Claxton, D; Braunschweig, I; van Besien, K; Anderlini, P; Andersson, BS; Champlin, R
      Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    4. Kornblau, S; Benson, AB; Catalano, R; Champlin, RE; Engelking, C; Field, M; Ippoliti, C; Lazarus, HM; Mitchell, E; Rubin, J; Stiff, PJ; Vokes, E; Wadler, S
      Management of cancer treatment-related diarrhea: Issues and therapeutic strategies

      JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
    5. Ghosh, S; Champlin, RE; Englund, J; Giralt, SA; Rolston, K; Raad, I; Jacobson, K; Neumann, J; Ippoliti, C; Mallik, S; Whimbey, E
      Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin

      BONE MARROW TRANSPLANTATION
    6. Abbott, B; Ippoliti, C; Hecth, D; Bruton, J; Whaley, B; Champlin, R
      Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation

      BONE MARROW TRANSPLANTATION
    7. Donato, ML; Gershenson, D; Ippoliti, C; Wharton, JT; Bast, RC; Aleman, A; Anderlini, P; Gajewski, JG; Giralt, S; Molldrem, J; Ueno, N; Lauppe, J; Korbling, M; Boyer, J; Bodurka-Bevers, D; Bevers, M; Burke, T; Freedman, R; Levenback, C; Wolf, J; Champlin, RE
      High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer

      BONE MARROW TRANSPLANTATION
    8. Przepiorka, D; Kernan, NA; Ippoliti, C; Papadopoulos, EB; Giralt, S; Khouri, I; Lu, JG; Gajewski, J; Durett, A; Cleary, K; Champlin, R; Andersson, BS; Light, S
      Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

      BLOOD
    9. Gajewski, JL; Nimer, S; Saliba, RM; Thomas, M; Przepiorka, D; Giralt, S; von Besien, K; Mehra, R; Andersson, B; Chan, KW; Ippoliti, C; Warkinten, D; Feig, S; Territo, M; Schiller, G; Lebkowski, J; Moseley, AM; Lloyd, K; von Hoeff, M; Okarma, T; Champlin, R
      Long-term outcome of a Phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients

      CYTOTHERAPY
    10. Nguyen, Q; Champlin, R; Giralt, S; Rolston, H; Raad, I; Jacobson, K; Ippoliti, C; Hecht, D; Tarrand, J; Luna, M; Whimbey, E
      Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients

      CLINICAL INFECTIOUS DISEASES
    11. Donato, ML; Champlin, RE; Van Besien, KW; Korbling, M; Cabanillas, F; Anderlini, P; Gajewski, JG; Lauppe, J; Durett, A; Andersson, B; Giralt, S; Khouri, I; Hagemeister, F; Romaguera, JE; Sarris, A; McLaughlin, P; Younes, A; Ippoliti, C; Blamble, DA; Hester, J; Gee, A; Rodriguez, MA
      Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    12. Przepiorka, D; Khouri, I; Ippoliti, C; Ueno, NT; Mehra, R; Korbling, M; Giralt, S; Gajewski, J; Fischer, H; Donato, M; Cleary, K; Claxton, D; Chan, KW; Braunschweig, I; van Besien, K; Andersson, BS; Anderlini, P; Champlin, R
      Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation

      BONE MARROW TRANSPLANTATION
    13. Warkentin, D; Ippoliti, C; Bruton, J; Van Besien, K; Champlin, R
      Toxicity of single daily dose gentamicin in stem cell transplantation

      BONE MARROW TRANSPLANTATION
    14. Abbott, B; Ippoliti, C; Bruton, J; Neumann, J; Whaley, R; Champlin, R
      Antiemetic efficacy of granisetron pins dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation

      BONE MARROW TRANSPLANTATION
    15. Przepiorka, D; Khouri, I; Thall, P; Mehra, R; Lee, MS; Ippoliti, C; Giralt, S; Gajewski, J; van Besien, K; Andersson, B; Korbling, M; Deisseroth, AB; Champlin, R
      Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia

      BONE MARROW TRANSPLANTATION
    16. IPPOLITI C
      ANTIDIARRHEAL AGENTS FOR THE MANAGEMENT OF TREATMENT-RELATED DIARRHEAIN CANCER-PATIENTS

      American journal of health-system pharmacy
    17. KHOURI IF; KEATING M; KORBLING M; PRZEPIORKA D; ANDERLINI P; OBRIEN S; GIRALT S; IPPOLITI C; VONWOLFF B; GAJEWSKI J; DONATO M; CLAXTON D; UENO N; ANDERSSON B; GEE A; CHAMPLIN R
      TRANSPLANT-LITE - INDUCTION OF GRAFT-VERSUS-MALIGNANCY USING FLUDARABINE-BASED NONABLATIVE CHEMOTHERAPY AND ALLOGENEIC BLOOD PROGENITOR-CELL TRANSPLANTATION AS TREATMENT FOR LYMPHOID MALIGNANCIES

      Journal of clinical oncology
    18. PRZEPIORKA D; KERNAN N; IPPOLITI C; PAPADOPOULOS E; GIRALT S; KHOURI I; LU J; GAJEWSKI J; DURETT A; CLEARY R; CHAMPLIN R; ANDERSSON B; LIGHT S
      PHASE-II STUDY OF DACLIZUMAB FOR TREATMENT OF ACUTE GRAFT-VS-HOST DISEASE

      Experimental hematology
    19. GAJEWSKI J; RONDON G; MIRZA N; MEHRA R; DONATO M; ANDERLINI P; KORBLING M; THERIALT R; KHOURI I; GIRALT S; BUZDAR A; UENO N; PRZEPIORKA D; ANDERSSON B; DURRETT A; SALIBA R; BRUTON J; RAHMAN Z; IPPOLITI C; HORTABAQYI G; RABER M; BAST R; CHAMPLIN R
      PRELIMINARY-RESULTS OF A RANDOMIZED TRIAL COMPARING INTENSIVE CHEMOTHERAPY WITH GROWTH-FACTOR (GF) OR PERIPHERAL-BLOOD PROGENITOR (PBPC) CELL MOBILIZATION TO GROWTH-FACTOR ALONE FOR HEMATOPOIETIC RESCUE AFTER HIGH-DOSE CHEMOTHERAPY (HDC)

      Experimental hematology
    20. PRZEPIORKA D; IPPOLITI C; KHOURI I; ANDERLINI P; FOLLODER J; UENO N; MEHRA R; GIRALT S; GAJEWSKI J; CLEARY K; CLAXTON D; CHAMPLIN R; ANDERSSON B; KORBLING M
      IMPACT OF PROPHYLAXIS REGIMEN ON THE INCIDENCE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION

      Bone marrow transplantation
    21. IPPOLITI C; CHAMPLIN R; BUGAZIA N; PRZEPIORKA D; NEUMANN J; GIRALT S; KHOURI I; GAJEWSKI J
      USE OF OCTREOTIDE IN THE SYMPTOMATIC MANAGEMENT OF DIARRHEA INDUCED BY GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES

      Journal of clinical oncology
    22. IPPOLITI C; MORGAN A; WARKENTIN D; VANBESIEN K; MEHRA R; KHOURI I; GIRALT S; GAJEWSKI J; CHAMPLIN R; ANDERSSON B; PRZEPIORKA D
      FOSCARNET FOR PREVENTION OF CYTOMEGALOVIRUS-INFECTION IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS UNABLE TO RECEIVE GANCICLOVIR

      Bone marrow transplantation
    23. WOO M; PRZEPIORKA D; IPPOLITI C; WARKENTIN D; KHOURI I; FRITSCHE H; KORBLING M
      TOXICITIES OF TACROLIMUS AND CYCLOSPORINE-A AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION

      Bone marrow transplantation
    24. WOO MH; IPPOLITI C; BRUTON J; MEHRA R; CHAMPLIN R; PRZEPIORKA D
      HEADACHE, CIRCUMORAL PARESTHESIA, AND FACIAL FLUSHING ASSOCIATED WITHHIGH-DOSE CARMUSTINE INFUSION

      Bone marrow transplantation
    25. PRZEPIORKA D; ANDERLINI P; IPPOLITI C; KHOURI I; FIETZ T; THALL P; MEHRA R; GIRALT S; GAJEWSKI J; DEISSEROTH AB; CLEARY K; CHAMPLIN R; VANBESIEN K; ANDERSSON B; KORBLING M
      ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION IN ADVANCED HEMATOLOGIC CANCERS

      Bone marrow transplantation
    26. PRZEPIORKA D; ANDERLINI P; IPPOLITI C; KHOURI I; FOLLODER J; UENO N; MEHRA R; GIRALT S; GAJEWSKI J; CLEARY K; CLAXTON D; ANDERSSON B; KORBLING M; CHAMPLIN R
      RISK-FACTORS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BLOOD STEM-CELL TRANSPLANT RECIPIENTS

      Blood
    27. KIENAST J; IPPOLITI C; MEHRA R; UENO N; CHAMPLIN R; KHOURI I; GIRALT S; GAJEWSKI J; CLAXTON D; ANDERLINI P; ANDERSSON B; PRZEPIORKA D
      DOSE-INTENSIFIED ANTITHYMOCYTE GLOBULIN (ATG) IN STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC MARROW OR BLOOD STEM-CELL TRANSPLANTATION

      Blood
    28. GIRALT S; MIRZA N; MEHRA R; GAJEWSKI J; ANDERSSON B; PRZEPIORKA D; KHOURI I; KORBLING M; COHEN A; RAHMAN Z; VANBESIEN K; IPPOLITI C; BRUTON J; ANDERLINI P; UENO N; CHAMPLIN R
      RESULTS OF CD8 DEPLETED ALLOGENEIC PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION (CD8- ALLO-PBSC) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)

      Blood
    29. GIRALT S; COHEN A; MEHRA R; GAJEWSKI J; ANDERSSON B; PRZEPIORKA D; KHOURI I; KORBLING M; DAVIS M; VANBESIEN K; IPPOLITI C; BRUTON J; ANDERLINI P; UENO N; CHAMPLIN R
      PRELIMINARY-RESULTS OF FLUDARABINE MELPHALAN OR 2CDA/MELPHALAN (2CDA/M) AS PREPARATIVE REGIMENS FOR ALLOGENEIC PROGENITOR-CELL TRANSPLANTATION (ALLO-PCT) IN POOR CANDIDATES FOR CONVENTIONAL MYELOABLATIVE CONDITIONING/

      Blood
    30. KHOURI IF; IPPOLITI C; GAJEWSKI J; PRZEPIORKA D; CHAMPLIN RE
      NEUTROPENIAS FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION - RESPONSE TO THERAPY WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN

      American journal of hematology
    31. MCCARTHY PL; WILLIAMS L; HARRISBACILE M; YEN J; PRZEPIORKA D; IPPOLITI C; CHAMPLIN R; FAY J; BLOSCH C; JACOBS C; ANASETTI C
      A CLINICAL-PHASE I II STUDY OF RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR IN GLUCOCORTICOID-RESISTANT GRAFT-VERSUS-HOST DISEASE/

      Transplantation
    32. PRZEPIORKA D; IPPOLITI C; KHOURI I; ANDERLINI P; MEHRA R; GIRALT S; GAJEWSKI J; FRITSCHE H; DEISSEROTH AB; CLEARY K; CHAMPLIN R; VANBESIEN K; ANDERSSON B; KORBLING M
      ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIA - IMPROVED SHORT-TERM OUTCOME WITH BLOOD STEM-CELL GRAFTS AND TACROLIMUS

      Transplantation
    33. PRZEPIORKA D; IPPOLITI C; KHOURI I; WOO M; MEHRA R; LEBHERZ D; GIRALT S; GAJEWSKI J; FISCHER H; FRITSCHE H; DEISSEROTH AB; CLEAN K; CHAMPLIN R; VANBESIEN K; ANDERSSON B; MAHER R; FITZSIMMONS W
      TACROLIMUS AND MINIDOSE METHOTREXATE FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER MATCHED UNRELATED DONOR MARROW TRANSPLANTATION

      Blood
    34. ABBOTT B; IPPOLITI C; NEUMANN J; BRUTON J; CHAMPLIN R
      STANDARD PRACTICE PROTOCOL OF GRANISETRON (KYTRIL(R)) FOR ANTIEMETIC CONTROL IN BONE-MARROW TRANSPLANT (BMT) PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY WITH OR WITHOUT TOTAL-BODY IRRADIATION (TBI)

      Blood
    35. PRZEPIORKA D; IPPOLITI C; KHOURI I; ANDERLINI P; LEBHERZ D; VANBESIEN K; UENO N; MEHRA R; GIRALT S; GAJEWSKI J; FRITSCHE H; CLEARY K; CLAXTON D; CHAMPLIN R; ANDERSSON B; KORBLING M
      MICRODOSE METHOTREXATE VS METHYLPREDNISOLONE IN COMBINATION WITH TACROLIMUS FOR PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE (GVHD) AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION

      Blood
    36. PRZEPIORKA D; NATH R; IPPOLITI C; MEHRA R; HAGEMEISTER F; DIENER K; DIMOPOULOS M; GIRALT S; KHOURI I; SAMUELS B; VANBESIEN K; ANDERSSON B; DEISSEROTH AB; LUNA M; CABANILLAS F; CHAMPLIN R
      A PHASE I-II STUDY OF HIGH-DOSE THIOTEPA, BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR AUTOLOGOUS TRANSPLANTATION FOR MALIGNANT-LYMPHOMA

      Leukemia & lymphoma
    37. PRZEPIORKA D; MADDEN T; IPPOLITI C; ESTROV Z; DIMOPOULOS M
      DOSING OF THIOTEPA FOR MYELOABLATIVE THERAPY

      Cancer chemotherapy and pharmacology
    38. PRZEPIORKA D; CHAN KW; CHAMPLIN RE; CULBERT SJ; PETROPOULOS D; IPPOLITI C; KHOURI I; HUH YO; VREISENDORP H; DEISSEROTH AB; BLEYER WA
      PREVENTION OF GRAFT-VERSUS-HOST-DISEASE WITH ANTI-CD5 RICIN-A CHAIN IMMUNOTOXIN AFTER CD3-DEPLETED HLA-NONIDENTICAL MARROW TRANSPLANTATION IN PEDIATRIC LEUKEMIA PATIENTS

      Bone marrow transplantation
    39. IPPOLITI C; PRZEPIORKA D; MEHRA R; NEUMANN J; WOOD J; CLAXTON D; GAJEWSKI J; KHOURI I; VANBESIEN K; ANDERSSON B; DEISSEROTH AB; DINNEY CP
      INTRAVESICULAR CARBOPROST FOR THE TREATMENT OF HEMORRHAGIC CYSTITIS AFTER MARROW TRANSPLANTATION

      Urology
    40. PRZEPIORKA D; IPPOLITI C; KHOURI I; ANDERLINI P; STEIN L; VANBESIEN K; MEHRA R; GIRALT S; GAJEWSKI J; FRITSCHE H; DEISSEROTH AB; CLEARY K; CHAMPLIN R; ANDERSSON B; KORBLING M
      TACROLIMUS VS CYCLOSPORINE FOR PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE (GVHD) AFTER ALLOGENEIC BLOOD STEM-CELL TRANSPLANTATION

      Blood
    41. PRZEPIORKA D; IPPOLITI C; KHOURI I; STEIN L; VANBESIEN K; MEHRA R; GIRALT S; GAJEWSKI J; FRITSCHE H; DEISSEROTH AB; CLEARY K; ANDERSSON B; CHAMPLIN R
      TACROLIMUS AND MINI-METHOTREXATE VS T-CELL DEPLETION, CYCLOSPORINE AND IMMUNOTOXIN FOR PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE (OVHD) AFTER HLA-NONIDENTICAL MARROW TRANSPLANTATION

      Blood
    42. IPPOLITI C; PEPPEY B; DEPOY E
      PROMOTING SELF-DETERMINATION FOR PERSONS WITH DEVELOPMENTAL-DISABILITIES

      Disability & society
    43. PRZEPIORKA D; DIMOPOULOS M; SMITH T; IPPOLITI C; DIENER K; LUNA M; CHAMPLIN RE
      THIOTEPA, BUSULFAN, AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FORMARROW TRANSPLANTATION - RISK-FACTORS FOR EARLY REGIMEN-RELATED TOXICITY

      Annals of hematology
    44. KHOURI IF; KEATING MJ; VRIESENDORP HM; READING CL; PRZEPIORKA D; HUH YO; ANDERSSON BS; VANBESIEN KW; MEHRA RC; GIRALT SA; IPPOLITI C; MARSHALL M; THOMAS MW; OBRIEN S; ROBERTSON LE; DEISSEROTH AB; CHAMPLIN RE
      AUTOLOGOUS AND ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - PRELIMINARY-RESULTS

      Journal of clinical oncology
    45. PRZEPIORKA D; IPPOLITI C; ESTROV Z; MADDEN T
      PHARMACOLOGICAL RATIONALE FOR THIOTEPA DOSING

      Experimental hematology
    46. PRZEPIORKA D; IPPOLITI C; GIRALT S; VANBEISEN K; MEHRA R; DEISSEROTH AB; ANDERSSON B; LUNA M; CORK A; LEE M; ESTEY E; ANDREEFF M; CHAMPLIN R
      A PHASE I-II STUDY OF HIGH-DOSE THIOTEPA, BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC MARROW TRANSPLANTATION

      Bone marrow transplantation
    47. PRZEPIORKA D; IPPOLITI C; PANINA A; GOODRICH J; GIRALT S; VANBESIEN K; MEHRA R; DEISSEROTH AB; ANDERSSON B; LUNA M; TARRAND JJ; CHAMPLIN RE
      GANCICLOVIR 3 TIMES PER WEEK IS NOT ADEQUATE TO PREVENT CYTOMEGALOVIRUS REACTIVATION AFTER T-CELL-DEPLETED MARROW TRANSPLANTATION

      Bone marrow transplantation
    48. PRZEPIORKA D; IPPOLITI C; KOBERDA J; CHAN KW; KHOURI IF; FISCHER HE; HUH YO; ESCUDIER SM; SEONG D; DAVIS M; GAJEWSKI J; VRIESENDORP HM; CHAMPLIN RE
      INTERLEUKIN-2 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AFTER HAPLOIDENTICAL MARROW TRANSPLANTATION

      Transplantation
    49. GAJEWSKI J; CECKA M; TONAI R; PRZEPIORKA D; FEIG S; TERASKI P; FISCHER H; GIRALT S; VANBESIEN K; CHAN K; HUNT L; IPPOLITI C; MEHRA R; KHOURI I; ANDERSSON B; DEISSEROTH A; NIMER S; SCHILLER G; LILL M; WOLIN M; BEEBE M; VONWOLFF B; TERRITO M; GJERTSON D; CHAMPLIN R
      IMPACT OF HLA CLASS-II DNA TISSUE TYPING ON ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) AND SURVIVAL IN UNRELATED DONOR BONE-MARROW TRANSPLANTS(BMT)

      Blood
    50. GAJEWSKI J; PRZEPIORKA D; GIRALT S; THORNY M; MOSELEY AM; LLOYD K; HUYNH L; THANDI D; MARSHALL M; RONDON G; KORBLING M; ANDERSSON B; NELLIS K; DEISSEROTH A; VANBESIEN K; MEHRA R; IPPOLITI C; WARKENTIN D; OKARMA T; GREENE S; VONWOLFF B; CHAN K; LEBKOWSKI J; CHAMPLIN R
      EFFECTIVE PARTIAL DEPLETION OF T-CELLS BY PANNING USING ANTI-CD5 8 ANTIBODY-COATED FLASKS IN HLA-MISMATCHED BONE-MARROW TRANSPLANTS (BMT)/

      Blood
    51. IPPOLITI C; MORGAN A; PRZEPIORKA D; WARKENTIN D; CHAMPLIN RE; GAJEWSKI J; GIRALT S; KHOURI I; MEHRA R; VANBESIEN K; GOODRICH J
      FOSCARNET FOR PREVENTION OF CMV IN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS UNABLE TO RECEIVE GANCICLOVIR

      Blood
    52. PRZEPIORKA D; CHAN KW; CHAMPLIN RE; CULBERT S; PETROPOULOS D; IPPOLITI C; KHOURI I; HUH Y; VREISENDORP H; DEISSEROTH AB; BLEYER A
      PREVENTION OF GVHD WITH ANTI-CD5 RICIN-A CHAIN IMMUNOTOXIN AFTER CD3-DEPLETED HLA-NONIDENTICAL BMT IN PEDIATRIC-PATIENTS

      Blood
    53. WARKENTIN D; PRZEPIORKA D; IPPOLITI C; CHAMPLIN RE; HUBER S
      COST-BENEFIT COMPARISON OF 2 DOSAGE REGIMENS OF INTRAVENOUS IMMUNOGLOBULIN AFTER ALLOGENEIC BMT

      Blood
    54. PRZEPIORKA D; SUZUKI J; IPPOLITI C; HESTER JP; FRITSCHE HA
      BLOOD TACROLIMUS CONCENTRATION UNCHANGED BY PLASMAPHERESIS

      American journal of hospital pharmacy
    55. IPPOLITI C; PRZEPIORKA D; SMITH T; MAIESE S; GIRALT S; ANDERSSON BS; DEISSEROTH AB; CHAMPLIN RE
      ADVERSE-EFFECTS OF MOLGRAMOSTIM IN MARROW TRANSPLANT RECIPIENTS

      Clinical pharmacy
    56. NATH R; PRZEPIORKA D; IPPOLITI C; MEHRA R; HAGEMEISTER F; DIENER K; DIMOPOULOS M; GIRALT S; KHOURI I; SAMUELS B; VANBESIEN K; ANDERSSON B; DEISSEROTH AB; LUNA M; CABANILLAS F; CHAMPLIN R
      PHASE I-II STUDY OF HIGH-DOSE THIOTEPA, BUSULFAN AND CYCLOPHOSPHAMIDE(TBC) WITH AUTOLOGOUS BMT FOR HIGH-RISK LYMPHOMA

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/10/20 alle ore 15:34:25